188 related articles for article (PubMed ID: 36457506)
1. Large-cell neuroendocrine carcinoma of the gynecologic tract: Prevalence, survival outcomes, and associated factors.
Pang L; Chen J; Chang X
Front Oncol; 2022; 12():970985. PubMed ID: 36457506
[TBL] [Abstract][Full Text] [Related]
2. Primary Neuroendocrine Tumors of the Endometrium: Management and Outcomes.
Zhang J; Pang L
Front Oncol; 2022; 12():921615. PubMed ID: 35814474
[TBL] [Abstract][Full Text] [Related]
3. Primary neuroendocrine tumors of the ovary: Management and outcomes.
Pang L; Guo Z
Cancer Med; 2021 Dec; 10(23):8558-8569. PubMed ID: 34773393
[TBL] [Abstract][Full Text] [Related]
4. Outcomes for Surgery in Stage IA Large Cell Lung Neuroendocrine Compared With Other Types of Non-Small Cell Lung Cancer: A Propensity Score Matching Study Based on the Surveillance, Epidemiology, and End Results (SEER) Database.
Zou L; Guo T; Ye L; Zhou Y; Chu L; Chu X; Ni J; Zhu Z; Yang X
Front Oncol; 2020; 10():572462. PubMed ID: 33324549
[TBL] [Abstract][Full Text] [Related]
5. Survival After Lobectomy vs. Sublobar Resection for Stage IA Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
Yu X; Zhang M; Wang F; Guo X; Ma K; Wang L; Zhao H; Xiao H; Huang C; Du L; Jia R; Yang Y; Zhang L; Yu Z
Front Surg; 2022; 9():856048. PubMed ID: 35372493
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, Associated Factors, and Survival Outcomes of Small-Cell Neuroendocrine Carcinoma of the Gynecologic Tract: A Large Population-Based Analysis.
Pang L; Wang S
Front Med (Lausanne); 2022; 9():836910. PubMed ID: 35479939
[TBL] [Abstract][Full Text] [Related]
7. Differences between Advanced Large Cell Neuroendocrine Carcinoma and Advanced Small Cell Lung Cancer: A Propensity Score Matching Analysis.
Yang W; Wang W; Li Z; Wu J; Xu X; Chen C; Ye X
J Cancer; 2023; 14(9):1541-1552. PubMed ID: 37325062
[No Abstract] [Full Text] [Related]
8. [Efficacy analysis of radiotherapy combined with surgery for locally advanced rectal mucinous adenocarcinoma: a retrospective study based on data of Surveillance, Epidemiology, and End results population].
Zhang Y; Wang X; Chi P; Lin H; Lu X; Huang Y; Xu Z; Huang S; Sun Y; Ye D
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):85-93. PubMed ID: 30703799
[TBL] [Abstract][Full Text] [Related]
9. The local treatment modalities in FIGO stage I-II small-cell carcinoma of the cervix are determined by disease stage and lymph node status.
Zhou J; Yang HY; Wu SG; He ZY; Lin HX; Sun JY; Li Q; Guo ZW
Cancer Med; 2016 Jun; 5(6):1108-15. PubMed ID: 26990881
[TBL] [Abstract][Full Text] [Related]
10. The role of radiotherapy in pulmonary large cell neuroendocrine carcinoma: propensity score matching analysis.
Cao L; Wu HF; Zhao L; Bai Y; Jiang ZL; Yang WJ; Liu SX
J Radiat Res; 2020 Jul; 61(4):594-601. PubMed ID: 32567658
[TBL] [Abstract][Full Text] [Related]
11. Double-edged role of radiotherapy in patients with pulmonary large-cell neuroendocrine carcinoma.
Jiang Y; Lei C; Zhang X; Cui Y; Che K; Shen H
J Cancer; 2019; 10(25):6422-6430. PubMed ID: 31772675
[No Abstract] [Full Text] [Related]
12. Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study.
Cao L; Li ZW; Wang M; Zhang TT; Bao B; Liu YP
PeerJ; 2019; 7():e6539. PubMed ID: 30944773
[TBL] [Abstract][Full Text] [Related]
13. Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States.
May MS; Kinslow CJ; Adams C; Saqi A; Shu CA; Chaudhary KR; Wang TJC; Cheng SK
Transl Lung Cancer Res; 2021 Jan; 10(1):71-79. PubMed ID: 33569294
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological characteristics and prognosis of pulmonary large cell neuroendocrine carcinoma aged ≥65 years.
Cao L; Zhao L; Wang M; Zhang XH; Yang ZC; Liu YP
PeerJ; 2019; 7():e6824. PubMed ID: 31149394
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of different metastatic sites for patients with FIGO stage IVB endometrial cancer after surgery: A SEER database analysis.
Li H; Zhang R; Chen C; Wu C; Lin H; Li J; Lin Z
J Surg Oncol; 2020 Oct; 122(5):941-948. PubMed ID: 32682330
[TBL] [Abstract][Full Text] [Related]
16. Developing and validating a prognostic nomogram for ovarian clear cell carcinoma patients: A retrospective comparison of lymph node staging schemes with competing risk analysis.
Li Y; Xiu L; Ma M; Seery S; Lou X; Li K; Wu Y; Liang S; Wu Y; Cui W
Front Oncol; 2022; 12():940601. PubMed ID: 36439411
[TBL] [Abstract][Full Text] [Related]
17. Nomograms predicting the overall survival and cancer-specific survival of patients with stage IIIC1 cervical cancer.
Feng Y; Wang Y; Xie Y; Wu S; Li Y; Li M
BMC Cancer; 2021 Apr; 21(1):450. PubMed ID: 33892663
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors and a Nomogram Predicting Overall Survival and Cancer-Specific Survival for Patients with Collecting Duct Renal Cell Carcinoma.
Xiao R; Liu C; He W; Ma L
Biomed Res Int; 2021; 2021():6736008. PubMed ID: 34805402
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix based on population analyses.
Lin LM; Lin Q; Liu J; Chu KX; Huang YX; Zhang ZK; Li T; Dai YQ; Li JL
Cancer Med; 2020 Sep; 9(18):6524-6532. PubMed ID: 32705800
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and prognostic factors of stage IC ovarian clear cell carcinoma: a Surveillance, Epidemiology, and End Results (SEER) analysis.
Chen Q; Wang S; Lang JH
Arch Gynecol Obstet; 2021 Aug; 304(2):521-529. PubMed ID: 33543331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
